Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ONCR-177 + pembrolizumab
- Development stage
- Discontinued
- Lead developer
- Oncorus
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
ONCR-177 + pembrolizumab is a **combination therapy** under investigation for the treatment of advanced and refractory solid tumors. **ONCR-177** is an intratumorally administered, genetically engineered oncolytic Herpes Simplex Virus (oHSV) immunotherapy that stimulates multiple arms of the immune system through local release of immune-activating transgenes and direct tumor lysis. **Pembrolizumab** is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, acting as an immune checkpoint inhibitor to restore anti-tumor immune responses. The combination is designed to enhance local and systemic anti-tumor immunity and possibly broaden responses to immunotherapy. The combination is being developed for patients with advanced cutaneous, subcutaneous, or metastatic nodal solid tumors who are refractory to, ineligible for, or relapsed from standard of care therapies[3].
- Other names
- ONCR-177 plus pembrolizumabONCR177 plus pembrolizumabONCR 177 plus pembrolizumabONCR-177 and pembrolizumabONCR177 and pembrolizumabONCR 177 and pembrolizumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)GM-CSF (Granulocyte-macrophage colony-stimulating factor)
Beyond the preview
Go deeper on ONCR-177 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONCR-177 + pembrolizumab.